Ferring Pharmaceuticals Launches Phase IIIB Trial Of Degarelix As Intermittent Therapy
Ferring Pharmaceuticals announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer. The announcement was made at the 2009 American Urological Association Annual Meeting in Chicago, IL.
More: continued here
Filed under: Endocrinology on May 3rd, 2009
You must be logged in to post a comment.